Multani Pharmaceuticals Limited, a active public limited company, was established on 05 March 1986 in New Delhi, Delhi, India. Engaging in personal care & skincare products within the manufacturing sector, it holds CIN: U24230DL1986PLC023539. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹6.00 Cr and a paid-up capital of ₹2.16 Cr.
Formerly known as Multani Pharmaceuticals P Limited. It upholds a compliant status. Employing 483 professional, Its leadership includes Rajesh Sabharwal (Director), Sanjay Kumar (Director), Pradeep Multani (Director). Past directors included Rajesh Sabharwal, Jagdish Prasad Pandey, Kamal Prasad. It holds ₹44.60 Cr open charges and ₹23.76 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at T-10 Okhla Industrial Area Phase - Ii, New Delhi, Delhi, 110020.
U24230DL1986PLC023539
023539
05 March 1986
₹6.00 Cr
₹2.16 Cr
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Multani Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajesh Sabharwal | Director | 27 Feb 2019 | Current |
| Sanjay Kumar | Director | 01 Feb 2023 | Current |
| Pradeep Multani | Director | 08 Mar 1986 | Current |
| Yogesh Sahni | Director | 27 Feb 2019 | Current |
| Vinay Rungta | Director | 01 Feb 2023 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 31 Mar 2020 | Past |
| Pramod Abcsdd | Director | 02 Feb 2023 | Past |
| Pramod Abcsdd | Managing Director | 02 Feb 2023 | Past |
| Pramod Abcsdd | Director | 31 Mar 2020 | Past |
| Pramod Abcsdd | Additional Director | 02 Jun 2012 | Past |
| Pramod Abcsdd | Director | 31 Mar 2020 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Multani Pharmaceuticals Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 19.51% increase. The company also saw a substantial fall in profitability, with a 10.51% decrease in profit. The company's net worth Soared by an impressive increase of 17.98%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Multani Pharmaceuticals had a promoter holding of 99.94% and a public holding of 0.06%. The company had 3 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹446,000,000.00
₹237,558,147.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Sep 2025 | Others | ₹20.00 Cr | Open |
| 18 Jan 2021 | Sidbi | ₹1.50 Cr | Open |
| 31 Dec 2002 | Others | ₹23.10 Cr | Open |
| 19 Jan 2024 | Others | ₹1.10 Cr | Satisfied |
| 21 May 2018 | Others | ₹1.20 M | Satisfied |
Explore comprehensive loan charge details -
Multani Pharmaceuticals has a workforce of 483 employees as of Apr 03, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Multani Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Multani Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge with Others amounted to Rs. 20.00 Cr with Charge ID 101162442 was registered on 20 Sep 2025. was recorded as a recent event.
The activity A charge registered on 19 Jan 2024 via Charge ID 100848799 with Others was fully satisfied on 03 Apr 2025. was completed.
Multani Pharmaceuticals Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.
Progress on Multani Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was documented.
A charge with Others amounted to Rs. 1.10 Cr with Charge ID 100848799 was registered on 19 Jan 2024. was recorded as a recent event.
A charge with Others of Rs. 23.10 Cr registered on 31 Dec 2002 with Charge ID 80014710 was modified on 08 Aug 2023. was recorded as a recent event.
The CIN of Multani Pharmaceuticals Limited is U24230DL1986PLC023539.
Multani Pharmaceuticals Limited is headquartered at T-10 Okhla Industrial Area Phase - Ii, New Delhi, Delhi, 110020.
Multani Pharmaceuticals Limited was incorporated on 05 March 1986.
The current directors of Multani Pharmaceuticals Limited are
The primary industry of Multani Pharmaceuticals Limited is Manufacturing.
Multani Pharmaceuticals Limited is unlisted.
The authorized capital of Multani Pharmaceuticals Limited is ₹6.00 Cr, and the paid-up capital is ₹2.16 Cr.
The compliance status of Multani Pharmaceuticals Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX